Synthetic biology - the next phase of biotechnology and genetic engineering. TAB-Fokus by Sauter, A. et al.
OFFICE OF TECHNOLOGY ASSESSMENT
AT THE GERMAN BUNDESTAG 
SYNTHETIC BIOLOGY – 
THE NEXT PHASE OF BIOTECHNOLOGY 
AND GENETIC ENGINEERING
Client and topiC initiative




















taB-Fokus no. 7 regarding report no. 164 novemBer 2015
(easily) understandable to non-experts. As a consequence, 
it is inherently difficult to examine and to discuss the pos-
sible impacts of synbio. For this reason, the TAB report 
introduces a basic differentiation between synbio in the 
narrow sense and synbio in the broader sense (see boxes 
on pages 2 and 3).
Applications of synbio i. n. s., i. e. of artificial, completely 
»designed« (complex) biological systems or organisms, 
are still a distant dream. Their social and political rele-
vance in the years to come is thus considered to be small. 
The situation is quite different for synbio i. b. s. – which 
is considered here as the next phase of biotechnology 
and genetic engineering. Due to increasingly simpler and 
faster techniques for targeted molecular-biological mo-
dification of organisms, a large number of applications 
is expected for the near future. Whereas synbio projects 
primarily focused on the modification of micro-organis-
ms for industrial and medical use so far, the scientific and 
regulatory debate from spring 2015 onwards concentrated 
also on applications of new genetic modification techno-
logies in plants, animals and humans.
So far, the recently developed so-called genome editing 
techniques (such as CRISPR/Cas) have hardly been dealt 
with under the label of synbio. Their potential for innova-
tion is not so much linked to the visionary notion to com-
pletely redesign organisms, but to the simplicity and speed 
in the targeted modification of genomes – including the 
human genome. In 2015, it became apparent that a new 
round of the debate on genetic engineering is imminent 
or has already started at the international and national lev-
el. As regards the responsible, further development and 
potential regulation, it appears evident that synbio (at 
least i. b. s.), »by definition«, cannot elude this debate.
What it is aBout
For more than ten years now, the term »synthetic biol-ogy« 
(synbio for short) refers to research projects, meth ods and 
procedures dealing with the »redesign« of natural or-
ganisms that goes far beyond what has been possible so 
far by »traditional« genetic engineering. The approaches 
involved are envisioned to ultimately give rise to the crea-
tion of (completely) artificial »biological« systems. Syn-
bio is the subject of a multitude of studies and opinions 
from political advisory bodies, ethics commis sions, acad- 
emies and funding organizations. In the public, how-
ever, the term is almost unknown. A main reason for this 
is that there exists no clear-cut, scientifically recognized 
demarcation to genetic engineering, let alone one that is 
summary
 ›  Scientific and technological progress allows to genet-
ically redesign natural organisms in ever more pro-
found ways (synbio in the broader sense). In the long 
term, the aim is to create artificial biological systems 
(synbio in the narrow sense).
 ›  Application areas are chemical and energy production, 
environmental protection as well as the medical sector. 
Considering the current, early state of research and de-
velopment, it is impossible to forecast reliably which 
approaches of synbio will prevail against procedures 
that make use of the available biological diversity or 
that are limited to more subtle interventions.
 ›  Risk assessment and the evaluation of substantially 
modified organisms will require the development and 
exploration of new methods and procedures.
 ›  Opportunities for different societal groups to partici-
pate in the responsible development of synbio are 
rang ing from stakeholder involvement in setting re-
search agendas to DIY biology.
 ›  Dealing with intellectual property within the frame-
work of an increasingly digital economy will also re-
present a major challenge for the future use of synbio.
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Medical sector: Synbio offers a number of approaches for 
novel pharmaceuticals and vaccines, therapeutic treatment 
strategies and diagnostics. Most projects are still in early 
phases of research. But there are also clinical trials i. a. with 
modified viruses for combating cancer. Semi-synthetic ar-
temisinin, an important ingredient of anti-malarial medi-
cine, is already produced 
on a commercial scale in 
modified yeast. More-
over, large-scale field ex-
periments for controlling 
dengue fever by means 
of genetically modified 
mosquitoes (synbio i. b. s.) 
are carried out.
Environmental sens-




(GMMO) can allow an 
easy and cost-effective 
measurement of toxic 
substances in soil or water 
samples. A first commercially available product is the ARSOlux 
biosensor for determining the arsenic content in drinking wa-
ter. If used properly, there will be no release of any GMMO. For 
the remediation of contaminated soils by means of GMMO, 
however, no approaches are known that are ready for applica-
tion. Environmental release is likely to be inevitable and the 
effective control of the GMMO will pose a pivotal challenge.
synBio: a key keChnology For the BioeConomy?
Earlier forecasts have seen the greatest potential of synbio in 
the production of bulk chemicals and in energy production. 
However, corresponding entrepreneurial activities and large 
investments have recently been significantly reduced as 
a consequence of the fluctuating and overall decreasing oil 
price. Both chemical and fuel production are addressing mass 
markets in which new procedures have to prevail against 
cost-optimized technologies, often established for decades.
Fields oF appliCation
Many research and development approaches of synbio focus 
on the use of renewable instead of fossil raw materials in 
chemical and energy production and thus on the core notion of 
the (future) »bioeconomy«. Furthermore, there are potential 
applications in medicine as well 
as in the field of environmental 
sensing and remediation. The 
objective is always to use synbio in 
order to overcome or at least extend 
some of the limitations inherent in 
biological processes.
Chemical and energy produc-
tion: A whole series of new bio-
based production processes has 
been successfully established 
by means of synbio i. b. s., par-
ticularly regarding high-value 
aromatic substances, fragrances 
and other ingredients for the 
food, cosmetics and detergents 
industry (such as vanillin or a 
palm oil substitute). For this, 
genes from various organisms are typically combined in a 
recipient organism (yeasts, algae, bacteria) to generate a new 
optimized metabolic pathway. On a pre-commercial scale, 
this approach has also been used for producing important 
commodity chemicals for the production of polymers 
(1,3-Propanediol, 1,4-Butanediol), biodegradable plastics 
(polylactides, polyhydroxyalkanoates) as well as of high-
quality biofuels (butanol, biodiesel, farnesenes). In Brazil, 
synthetic diesel fuel is already being tested in local public 
transport.
Moreover, in the energy sector, research efforts focus on the 
conversion of raw materials, mainly lignocellulosic biomass 
– the material which represents the largest part of plant 
biomass and which is not edible (e. g. corn stalks and leaves). 
The aim is to avoid direct competition with food production 
and, at the same time, tap a source of raw materials which is 
available in large quantities.
When it comes to define the orientation of research areas 
and agendas, European and German research policies in-
creasingly strive to include CSO perspectives. Not only 
in view of future funding programs for research into the 
risks, safety and security of synbio, the involvement of 
representatives from civil society organizations dealing 
with environmental, developmental and social issues 
is of particular importance. Without public funding, 
stakeholder engagement in developing the researCh agenda: resourCes are required
however, a continuous involvement will be difficult for 
them, as they often have only few paid employees the 
work of whom is financed to a large extent by means of 
membership fees. For this reason, it appears sensible that 
research policy would make available funds not only spo-
radically, but with a long-term commitment regarding an 
organized participation of representatives from NGOs.
status quo: synBio in the Broader sense
Synbio i.b.s. refers to all currently pursued approaches regard-
ing the molecular-biological modification of known organisms 
which are mostly application-oriented and increasingly based 
on digital information. So far, simple approaches for genetic-
ally modifying metabolic pathways of organisms (so-called 
metabolic engineering) were only based on the modification 
of a small number of genetic elements and often aimed at the 
optimization of (native) metabolic pathways already existing 
in natural organisms. But meanwhile several genetic elements 
and genes from different organisms are combined and trans-
ferred to suitable production organisms in order to produce 
chemicals by means of bio-synthesis, or to generate genetic 
circuits for new sensory and regulatory cell functions (see ex-
amples in the text). Furthermore, computer-assisted design 
and modelling processes are increasingly used to generate 
such complex biological functions.
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context, an intensive debate on dual use research of concern 
(DURC) has emerged internationally and in Germany.
Besides recommending the creation of a national statutory 
DURC commission, the German Ethics Council particularly 
emphasized the necessity to systematically integrate the sub-
jects of biosecurity and »dual use« into university cur ricula 
and other training programs 
in the life sciences and to cre-
ate an overall culture of shared 
responsibility. This is a very 
challenging task, in particu-
lar with respect to universities 
and other research institu-
tions, due to the high publi-
cation pressure and the often 
precarious employment situa-
tion.
If gene synthesis should be-
come increasingly decentral-
ized (and possibly signifi-
cantly more efficient and less 
costly) it might also be neces-
sary to deal with the ques tion 
as to whether registration and control of devices, their 
users and specific applications (i. e. of the gene sequences 
produced) should be and can be performed. Malicious actors 
will try to elude such a control. For this reason, intelligence 
and security measures have to be considered as well without 
excessively restricting well-meaning actors.
risk assessment Will BeCome (even more!) diFFiCult – 
in need For Further researCh 
So far, the risk assessment of genetically modified organisms 
(GMO) is based on a case-by-case examination and on the 
comparison with largely similar (»substantially equivalent«) 
organisms which have been used for a long time already 
(which are »familiar«). In recent years, it has been pointed out 
that this procedure is put into question by several scientific 
and technological developments of synbio. The advances in ge-
nome editing techniques may significantly increase the pres-
The (few) projects and products which may already become 
competitive today are low-volume, but high-value special-
ty chemicals, flavoring substances, pharmaceuticals and 
vaccines. For these, neither cost nor biosafety/biosecurity 
issues are playing a major role, because existing or alternative 
procedures are complex as well and because production pro-
cesses are restricted to contained systems (bioreactors), or 
unintended side effects are ac-
cepted more readily (pharma-
ceuticals/therapeutics). With 
respect to medicines, vaccines 
or gene therapies in particular, 
prospects of success are hardly 
predictable; since very often 
the effectiveness and relative 
superiority become evident at 
rather late stages of develop-
ment or during application 
only.
The future development of 
synbio will on the one hand 
depend on the commit-
ment of public and private 
investors and on societal 
accept ance on the other. Against this background, society‘s 
involve ment in a responsible further development of synbio 
by means of different kinds of participation appears to be es-
sential (see box).
super-viruses From the synBio laB? 
don‘t paniC, But WatCh out!
Right from the beginning, the scientific and non-scientific 
debate on synbio has always been accompanied by issues of 
intentional misuse (»biosecurity«). These refer to a crimi-
nal (»biocrime«) or even malicious (»bioterrorism«) use of 
biological agents or of the underlying knowledge in public, 
private or illegal research laboratories. However, the most 
widely discussed risks have been related to medically and 
epidemiologically motivated research with highly patho-
genic viruses carried out in high-level containment labora-
tories and which usually are not ascribed to synbio. In this 
In recent years, projects of Citizen Science have been pro-
moted in a targeted way by research policy. In this con-
text, DIY biology represents a particularly active variant 
and combines very heterogeneous interests ranging from 
a mere leisure activity, a claim for participation based on 
democratic theory to the development of potential busi-
ness concepts. At least some representatives – due to their 
combination of a certain affinity for biotechnology and so-
diy Biology as aCtive Citizen sCienCe: support oF »haCkerspaCes« and Citizens’ laBoratories?
cial criticism – stand for a new voice in the debate on 
genetic engineering and synbio. The question is whether 
a comprehensive involvement of society in scientific pro-
gress in synbio should also include the support of bio-ha-
ckerspaces. It would also be possible to explore variants of 
»citizens‘ laboratories« which are more closely attached to 
university or research institutes, but are open for the ideas 
of their users.
vision oF the Future: synBio in the narroW sense
Synbio i.n.s. refers to the production of cells or organ- 
isms developed from scratch and designed »de novo« (or of 
cell-free biological or biochemical systems). These organ- 
isms are intended for the production of any, even complete-
ly novel substances or visionary applications in the fields of 
health, energy or the environment. Characteristic research 
approaches and methods in this context are the produc tion 
of entire synthetic genomes, the construction of so-called 
»minimal cells« or »protocells« (either »top down« by 
reducing natural cells or »bottom up« or »from scratch« 
from basic biochemical components) as well as the use of 
non-natural molecules (»xenobiology«). Protocell approaches 
involving molecules not present in extant cells may also 
provide knowledge on the emergence of life (and its chemis-
try) on Earth.
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potentially controversial at the societal level – should be orien-
ted towards solutions for societal challenges. The involvement 
of stakeholders outside the science system or the classical inno-
vation system is of particular importance, as these stakeholders 
could bring in their expertise and everyday knowledge, e. g. on 
agricultural or healthcare issues which cannot be provided by 
scientific analyses and approaches alone.
Sustainable models for the protection and use of intellec tual 
property related to digital data: There is an intense debate 
in the life sciences, but also beyond, on dealing with intellec-
tual property (IP) within the framework of an increasingly 
digital economy. The objective is to make use of the increase 
of knowledge in a way which is as sustainable as possible, i. e. 
socially equitable, ecologically compatible and economically 
profitable in the long term. The development of innovative IP 
models is one of the major challenges for science, economy, so-
ciety and politics and thus also for technology assessment in 
the years to come.
sure to adapt risk assessment procedures. The central question 
is to what extent and by means of which methods substan-
tially modified (or even largely »redesigned«) organisms 
 capable of propagation and proliferation can be and must 
be characterized with a view to a societally acceptable deci-
sion-making process regarding the use of these organisms.
This would require a new research policy agenda for bio-
safety research with regard to synbio i. b. s.. In order to be 
able to develop this agenda, it would be necessary to rein-
vestigate the existing unresolved controversies concerning 
the risk assessment of »conventional« GMO and to carry 
out a comprehensive and especially discursive balancing 
with regard to the weak points and controversial issues of 
risk assessment. It may not be expected that the controver-
sial issues will be resolved, but the objective should be to 
improve communication between the different actors with 
regard to the (still) open questions in biosafety research on 
GMO.
The relevant issues in the risk assessment of GMO are only 
partly linked to scientific aspects. Therefore, a future biosafe-
ty research program would also have to be oriented towards 
social sciences and the humanities; conceived on the long 
term and across policy areas; and offer real opportunities 
for participation, allowing to bring in the competences and 
interests of all relevant societal stakeholders. The coordi-
nation of such a process for developing a research program 
would have to be carried out by an institution or a (steering) 
body which is recognized as neutral and fair by as many ac-
tors involved as possible.
points oF reFerenCe For the sustainaBle develop-
ment oF synBio researCh and innovation
Expanding options for action and keeping them open: The 
most important principle of public R&D funding should be 
to broaden available options and to keep them open. This 
prohibits a premature commitment to specific technologies 
or processes – particularly in view of the complex challenges 
connected to a global sustainable bio-economy.
Solving problems instead of committing to technologies: The 
development of technologies – especially of those which are 
